COOPER COMPANIES, INC. (COO) SEC Filings

COOPER COMPANIES, INC. director Walter M. Rosebrough Jr. reported open-market purchases of a total of 10,000 shares of Common Stock on September 11 and September 14, 2026, at weighted average prices of $54.11 and $54.29 per share, respectively. The shares were acquired indirectly through the Walter M Rosebrough, Jr Revocable Trust, of which he is sole trustee, and a separate line reports 832 shares held directly. No Rule 10b5-1 trading plan is indicated.

COOPER COMPANIES, INC. (COO) reported that director Lawrence Erik Kurzius purchased 10,000 shares of common stock on September 14, 2026 in an open-market or private transaction at a price of $53.915 per share. After this transaction, he directly holds a total of 21,099 shares, and no Rule 10b5-1 trading plan is reported.

COOPER COMPANIES, INC. (COO) director Paul A. Keel purchased 4,701.015 shares of the company’s common stock in a direct, open-market or private transaction on September 11, 2026, at a weighted average price of about $53.18 per share.

After this purchase, he directly holds 4,701.015 shares. The filing notes the price is a weighted average, with individual trade prices ranging from $53.165 to $53.18 per share. No Rule 10b5-1 trading plan is reported for this transaction.

COOPER COMPANIES, INC. (COO) reported essentially flat quarterly revenue but sharply higher profitability for the quarter ended July 31, 2026. Net sales were $1.07 billion versus $1.06 billion a year earlier, with CooperVision steady and CooperSurgical modestly higher. Operating income rose to $222.0 million from $175.7 million, driven by higher gross margin and lower operating expenses, particularly at CooperSurgical following prior-year write-offs.

Net income jumped to $432.8 million (diluted EPS $2.24) from $98.3 million (EPS $0.49), primarily due to a $307.2 million discrete income tax benefit from the favorable resolution of a UK tax examination and an additional $40.9 million tax benefit tied to a litigation accrual. For the nine months, net sales grew to $3.17 billion, but operating income declined to $403.8 million from $542.5 million, mainly reflecting a $272.0 million litigation expense, net of insurance recoveries, related to CooperSurgical product claims.

Operating cash flow for the first nine months strengthened to $785.4 million, supporting significant capital spending of $257.3 million, payment of litigation-related amounts, and aggressive share repurchases of 6.2 million shares for $444.7 million. Total debt was $2.54 billion, including $1.50 billion of term loans, with $950.0 million of those loans having maturity extended to February 3, 2031, and $966.7 million drawn on a $2.3 billion revolving credit facility. The board expanded the long‑standing share repurchase authorization to $3.0 billion, with about $1.5 billion remaining available. The company also disclosed a UK payroll tax matter with a potential outcome ranging from £0 to £71.7 million, plus interest, and detailed settlements covering substantially all claims associated with a December 2023 CooperSurgical product recall.

Cooper Companies, Inc. (COO) reported fiscal third quarter 2026 results with modest top-line growth but strong profitability and cash generation. Revenue rose 1% year over year to $1.066 billion, including 1% organic growth. GAAP diluted EPS jumped to $2.24 from $0.49, largely driven by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination tied to a 2021 intellectual property transfer.

On an adjusted basis, non-GAAP diluted EPS was $1.15, up 4%, and non-GAAP operating margin improved 30 bps to 26%, reflecting expense management and productivity initiatives. Free cash flow grew 66% to $273.0 million, with operating cash flow of $341.7 million and capital expenditures of $68.7 million. CooperVision revenue was flat at $717.0 million as the company proactively reduced U.S. channel inventory, while CooperSurgical revenue increased 2% to $349.2 million, with fertility revenue up 5% organically.

CooperCompanies completed its strategic review and the Board unanimously decided to retain CooperSurgical after determining that offers received did not meet its view of shareholder value. As part of a revised capital allocation strategy, the company repurchased $339.1 million (about 4.9 million shares) in the quarter and expanded its share repurchase authorization from $2 billion to $3 billion, leaving approximately $1.5 billion available. Updated fiscal 2026 guidance calls for total revenue of $4.229–$4.252 billion (organic growth 2–3%) and non-GAAP diluted EPS of $4.51–$4.55, with continued emphasis on free cash flow exceeding $2.2 billion over fiscal 2026–2028.

COOPER COMPANIES, INC. director Paul A. Keel received a grant of 2,814 Restricted Stock Units as equity compensation. Each unit represents a right to receive one share of common stock, so the award covers 2,814 underlying shares. Following this grant, Keel holds 2,814 Restricted Stock Units directly. The award has no expiration date and the units will either vest and convert into common stock or be forfeited under the plan’s terms.

COOPER COMPANIES, INC. director Paul A. Keel filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. The available data show no reported transactions, derivative positions, or holding entries in this filing excerpt.

The Cooper Companies reported second-quarter fiscal 2026 results marked by solid sales growth but a litigation-driven loss. Net sales rose to $1,081.5 million from $1,002.3 million, with CooperVision up 8% and CooperSurgical up 8%, reflecting strength in contact lenses and fertility products.

However, a $271.6 million litigation expense tied to CooperSurgical’s recalled embryo culture media drove operating income to a $31.0 million loss and net loss to $77.9 million, or $(0.40) per diluted share, versus prior-year earnings of $0.44 per share. For the first six months, the company remained profitable, earning $52.9 million, supported by gross margin of 68% and operating cash flow of $443.7 million, up from $286.8 million.

Debt totaled $2,460.2 million, with $911.7 million drawn on the 2024 revolving credit facility and $1,500.0 million outstanding on the 2021 term loans. Cooper also repurchased 1.3 million shares for $105.6 million in the first half and expects existing cash, cash flow and credit capacity to cover its needs over at least the next year.

CooperCompanies reported fiscal second quarter 2026 results showing solid underlying growth but a large litigation impact. Revenue was $1.082 billion, up 8% year over year and 5% organically, with both CooperVision and CooperSurgical growing 8%.

GAAP diluted EPS was a loss of $(0.40) versus a profit of $0.44 a year ago, driven by a $271.6 million net pre-tax charge related to product-liability litigation from CooperSurgical’s December 2023 embryo culture media recall. This included $324.1 million of accrued litigation liabilities, partly offset by $52.5 million of expected insurance recoveries.

On a non-GAAP basis, diluted EPS rose 26% to $1.21 and operating margin increased to 27%, reflecting disciplined cost management and benefits from prior reorganization. Free cash flow was $96.4 million, and the company repurchased $13.1 million of stock. Management updated 2026 guidance, targeting total revenue of $4.285–$4.321 billion and non-GAAP EPS of $4.58–$4.66, and reaffirmed a long-term free cash flow objective exceeding $2.2 billion for fiscal 2026–2028.